<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124706">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01479075</url>
  </required_header>
  <id_info>
    <org_study_id>Centrin</org_study_id>
    <nct_id>NCT01479075</nct_id>
  </id_info>
  <brief_title>The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism</brief_title>
  <acronym>Centrin</acronym>
  <official_title>The Effect of Central Insulin on Insulin Sensitivity and Energy Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -Insulin has a direct effect on the energy metabolism of the brain under basal conditions
      and has an effect on the hepatic glucose production, lipid metabolism and the secretion of
      various hormone

      The purpose of this study is to determine whether central insulin influences the human
      peripheral insulin sensitivity of liver and muscle
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -Insulin has a direct effect on the energy metabolism of the brain under basal conditions
      and has an effect on the hepatic glucose production, lipid metabolism in the mouse model The
      purpose of this study is to determine whether central insulin influences the human
      peripheral insulin sensitivity of liver and muscle and energy metabolism
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>6 months</time_frame>
    <description>Assessment of insulin sensitivity with gold standard methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Energy metabolism</measure>
    <time_frame>6 months</time_frame>
    <description>Energy metabolism is assessed from gold standard methods</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>insulin in patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>central insulin is applied to diabetic patients at baseline and during hyperinsulinemic clamps</description>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin in study participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>central insulin is applied to healthy patients at baseline and during hyperinsulinemic clamps</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo in patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo in study participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>central insulin</intervention_name>
    <description>4x 40mU intranasal insulin</description>
    <arm_group_label>insulin in patients</arm_group_label>
    <arm_group_label>insulin in study participants</arm_group_label>
    <other_name>intranasal insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo in patients</arm_group_label>
    <arm_group_label>placebo in study participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 30 and ≤ 70 years

          -  balanced gender ratio (50: 50)

          -  BMI 20-25 kg/m² (normal weight subjects)

          -  BMI 25-35 kg/m² (obese subjects)

        Exclusion Criteria:

          -  acute illness within the last 2 weeks before the examination

          -  autoimmune diseases and disorders immune- compromised (leukocytes &lt;5000/μl)

          -  renal insufficiency (creatinine&gt; 1.5 mg / dl)

          -  heart disease, condition after heart attack

          -  anemia (Hb &lt;12 g / l, controls at each examination), blood donation within 4 weeks
             before the examination

          -  participation in another study within 2 months before the examination

          -  wear a metal or magnetic objects on or in the body

          -  claustrophobia

          -  use of immunomodulatory drugs (cortisol, antihistamines, aspirin)

          -  thyroid disease

          -  taking glitazones and insulin therapy

          -  pregnancy, lactation, menstruation

          -  cigarette smoking, use of alcohol or drugs, psychiatric disorders

          -  risk for / or manifest AIDS (HIV) or hepatitis B or C

          -  liver disease is not attributed to the existence of a non-alcoholic steatosis

          -  night shift work or circumstances, which do not allow the normal day-night rhythm

          -  bleeding disorders or disorders in wound healing

          -  hypersensitivity to local anesthetics

          -  malignant cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Roden, MD, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Germyn Diabetic Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julia Szendrödi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Diabetes Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Roden, MD, Prof</last_name>
    <phone>0211/33 82201</phone>
    <email>mroden@ddz.uni-duesseldorf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julia Szendrödi, MD, PhD</last_name>
    <phone>0211/33 82203</phone>
    <email>jszend@ddz.uni-duesseldorf.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>German Diabetic Center</name>
      <address>
        <city>Düsseldorf</city>
        <state>Nordrhein- Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Roden, Prof, MD</last_name>
      <phone>0211/33 82201</phone>
      <email>michael.roden@ddz.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Julia Szendrödi, MD, PhD</last_name>
      <phone>0211/33 82203</phone>
      <email>julia.szendroedi@ddz.uni-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Julia Szendrödi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 23, 2011</lastchanged_date>
  <firstreceived_date>November 22, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Diabetes Center</investigator_affiliation>
    <investigator_full_name>julia szendrödi</investigator_full_name>
    <investigator_title>Dr PhD</investigator_title>
  </responsible_party>
  <keyword>central insulin</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>energy metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
